Mineralys Therapeutics, Inc. Common Stock (MLYS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.36B
Last updated: Nov 17, 2026 at 11:06 AM ET
Mineralys Therapeutics, Inc. Common Stock (MLYS) Earnings: Report Dates and Results
Mineralys Therapeutics, Inc. Common Stock (MLYS) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Mineralys Therapeutics, Inc. Common Stock reported EPS of -$0.64, below the -$0.53 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MLYS has an expected report date of Mar 10, 2027.
MLYS Earnings Call
The latest MLYS earnings call transcript on file is labeled 2026Q2.
Read the 2026Q2 transcriptEarnings History
Of the 16 quarters below that had an estimate, MLYS beat 9 and missed 7. The widest gap in the table came in the quarter ended Jun 30, 2026, when EPS landed 400.00% below the estimate.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported |
|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.64 | -$0.53 | -$0.60 - -$0.39 | -20.75% | Miss | N/A | 8 | 4 up, 2 down | Nov 4, 2026 |
| Jun 30, 2026 | -$2.85 | -$0.57 | -$0.61 - -$0.44 | -400.00% | Miss | N/A | 8 | N/A | Aug 12, 2026 |
| Mar 31, 2026 | -$0.47 | -$0.44 | -$0.48 - -$0.38 | -6.82% | Miss | N/A | 6 | 3 up, 0 down | May 6, 2026 |
| Dec 31, 2025 | -$0.40 | -$0.94 | N/A | +57.45% | Beat | N/A | 8 | 1 up, 0 down | Mar 12, 2026 |
| Sep 30, 2025 | -$0.52 | -$0.61 | -$0.70 - -$0.51 | +14.75% | Beat | N/A | 7 | 6 up, 1 down | Nov 10, 2025 |
| Jun 30, 2025 | -$0.66 | -$0.74 | -$0.74 - -$0.60 | +10.81% | Beat | N/A | 7 | 3 up, 1 down | Aug 12, 2025 |
| Mar 31, 2025 | -$0.79 | -$0.98 | -$1.14 - -$0.80 | +19.39% | Beat | N/A | 5 | 1 up, 1 down | May 12, 2025 |
| Dec 31, 2024 | -$0.98 | -$1.08 | -$1.20 - -$0.68 | +9.26% | Beat | N/A | 7 | 0 up, 7 down | Feb 12, 2025 |
| Sep 30, 2024 | -$1.13 | -$0.83 | -$0.93 - -$0.66 | -36.14% | Miss | N/A | 7 | 0 up, 0 down | Nov 11, 2024 |
| Jun 30, 2024 | -$0.83 | -$0.70 | -$0.84 - -$0.65 | -18.57% | Miss | N/A | 7 | 0 up, 0 down | Aug 13, 2024 |
| Mar 31, 2024 | -$0.70 | -$0.67 | -$0.81 - -$0.51 | -4.48% | Miss | N/A | 5 | 0 up, 0 down | May 9, 2024 |
| Dec 31, 2023 | -$0.61 | -$0.82 | -$1.06 - -$0.55 | +25.61% | Beat | N/A | 4 | 0 up, 0 down | Mar 21, 2024 |
| Sep 30, 2023 | -$0.57 | -$0.76 | -$1.15 - -$0.45 | +25.00% | Beat | N/A | 4 | 0 up, 0 down | Nov 7, 2023 |
| Jun 30, 2023 | -$0.31 | -$0.72 | N/A | +56.94% | Beat | N/A | N/A | N/A | Aug 7, 2023 |
| Mar 31, 2023 | -$0.51 | -$0.89 | N/A | +42.70% | Beat | N/A | N/A | N/A | May 15, 2023 |
| Dec 31, 2022 | -$1.74 | -$1.72 | N/A | -1.16% | Miss | N/A | N/A | N/A | Feb 10, 2023 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.37, after -$3.64 the year before. It was -$1.74 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.37 | N/A |
| Dec 31, 2024 | -$3.64 | N/A |
| Dec 31, 2023 | -$2.00 | N/A |
| Dec 31, 2022 | -$1.74 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q2 for the period ended Jun 30, 2026, runs about 5,000 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q2 | Jun 30, 2026 | 4,991 | 15 | |
| 2026Q1 | Mar 31, 2026 | 5,562 | 14 | |
| 2025Q4 | Dec 31, 2025 | 6,198 | 14 | |
| 2025Q3 | Sep 30, 2025 | 4,283 | 12 | |
| 2025Q2 | Jun 30, 2025 | 4,998 | 15 | |
| 2025Q1 | Mar 31, 2025 | 6,220 | 10 | |
| 2024Q4 | Dec 31, 2024 | 5,492 | 12 | |
| 2024Q3 | Sep 30, 2024 | 5,211 | 11 |
2026Q2 Earnings Call
Opening remarks
Daniel Ferry Host - LifeSci Advisors Thank you. I would like to welcome everyone joining us today for our second quarter 2026 conference call. This afternoon, after the close of market trading, we issued a press release providing our second quarter 2026 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately one hour after its completion. After our prepared remarks, we will open the call for Q&A. Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, August 11, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events. I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.
Jon Congleton Chief Executive Officer Thank you, Daniel. Good afternoon, everyone. Welcome to our second quarter 2026 financial results and corporate update conference call. I am joined today by Adam Scott Levy, our Chief Financial Officer, and Eric J. Warren, our Chief Commercial Officer. I will begin with an overview of the business and recent milestones, Eric will then provide a commercial update, and Adam will review our second quarter financial results before we open the call for your questions. Before I get started with the business update, I would like to take a moment to welcome Dr. Terry Ferguson to the team. Terry joins us as Chief Medical Officer, succeeding Dr. David Rodman, who will continue to play an important role as a full-time strategic advisor to the company. Terry brings more than 35 years of experience in cardiovascular medicine, clinical development, and executive leadership. He served as Cardiovascular Therapeutic Area Head at Amgen and held senior cardiovascular leadership roles at AstraZeneca and The Medicines Company. He also spent more than 20 years on the faculty of the Texas Heart Institute in cardiovascular medicine. Terry's deep expertise in cardiovascular medicine and proven track record of advancing innovative therapies positions him well to lead our medical and late-stage clinical activities as we continue preparing for the potential commercialization of lorundrostat. I want to thank David for his dedication and hard work over the past several years.
Frequently Asked Questions About MLYS
When is Mineralys Therapeutics, Inc. Common Stock's next earnings date?
Mineralys Therapeutics, Inc. Common Stock's next earnings report is expected for Mar 10, 2027.
Did MLYS beat earnings estimates last quarter?
No. Mineralys Therapeutics, Inc. Common Stock reported EPS of -$0.64 for the quarter ended Sep 30, 2026, below the -$0.53 estimate by 20.75%.
What EPS do analysts expect from MLYS next quarter?
The consensus EPS estimate for Mineralys Therapeutics, Inc. Common Stock for the quarter ending Dec 31, 2026 is -$0.60 from 11 analysts, with estimates from -$0.72 to -$0.47.
How often does MLYS beat earnings estimates?
Mineralys Therapeutics, Inc. Common Stock beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -39.49%.
MLYS pages: Overview, Earnings, Forecast, Financials, Competitors